ENDPOINTS

GoodRx CEO Wendy Barnes on the future of the drug discount company

GoodRx has been in a rut. In its almost five years as a public company, its revenue flatlined, and its stock price plunged about 90%. Its founders stepped down as co-CEOs in 2023, and temporary ...

Mar 13, 2025 - 13:02
 0
GoodRx CEO Wendy Barnes on the future of the drug discount company
GoodRx has been in a rut. In its almost five years as a public company, its revenue flatlined, and its stock price plunged about 90%. Its founders stepped down as co-CEOs in 2023, and temporary ...
Read More

Tags:

Previous Article

SpaceX launches 21 Starlink broadband satellites to orbit from Florida (photos)

Next Article

Montara Therapeutics adds $20M to seed fundraise for neurology pipeline

Related Posts

Kaiser Permanente calls on FDA and Congress to firm up accelerated approval requirements

Kaiser Permanente calls on FDA and Congress to firm up ...

Feb 12, 2025  0

Updated: Lilly joins Trump administration to announce $27B manufacturing commitment

Updated: Lilly joins Trump administration to announce $...

Feb 26, 2025  0

FDA approves Ono’s rare joint tumor drug, setting up battle with Daiichi

FDA approves Ono’s rare joint tumor drug, setting up ba...

Feb 18, 2025  0